Effect of Continuous Intravenous Infusion of Esketamine on Postoperative Delirium and Quality of Recovery in Surgical Patients: A Randomized, Double-Blind, Controlled Trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2500109383

Enrollment

Unknown

Registered

2025-09-17

Start date

2025-09-28

Completion date

Unknown

Last updated

2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative delirium

Interventions

Experimental group :Esketamine 0.25 mg/kg/h

Control group:Placebo

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Aged 18 years or older; 2.Patients undergoing surgery under general anesthesia; 3.Voluntarily participated in the study and provided informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with pre-existing epilepsy, Parkinson's disease, myasthenia gravis, or psychiatric disorders; 2. Inability to communicate due to coma, severe dementia, or language barriers before surgery; 3. Severe liver dysfunction (Child-Pugh Class C), renal dysfunction (preoperative dialysis), ASA Class V, or life expectancy <=24 hours; 4. Allergy to esketamine used in this study.

Design outcomes

Primary

Measure	Time frame
Incidence of delirium;	—

Secondary

Measure	Time frame
Confusion Assessment Method, CAM score;Quality of Recovery-15 (QoR-15), QoR-15 Score;	—

Countries

China

Contacts

Public ContactYang Wang

People’s Hospital of Xinjiang Uygur Autonomous Region

1040426429@qq.com+86 186 9088 4120

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026